Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 7/20 | 0.43 |
| ▸ | PDE1A | P54750 | 4/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5731099 | 0.89 | PDE5A (0.51) | PDE5APDE1APDE1BPDE1CPDE10A | |
| SCHEMBL5729919 | 0.84 | PDE5A (0.42) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL5728915 | 0.84 | PDE5A (0.42) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL5730922 | 0.83 | PDE5A (0.44) | PDE5APDE1APDE1BPDE1CNPC1 | |
| SCHEMBL5730854 | 0.83 | PDE5A (0.43) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL5730920 | 0.83 | PDE5A (0.44) | PDE5APDE1APDE1BPDE1CNPC1 | |
| SCHEMBL5731103 | 0.83 | PDE5A (0.43) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL5730856 | 0.83 | PDE5A (0.43) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL5728930 | 0.82 | PDE5A (0.43) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL5728934 | 0.82 | PDE5A (0.43) | PDE5APDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060293326-A1 | 2-Heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases | BAYER HEALTHCARE AG (DE) | 2006-12-28 | — | — | US | disclosed |
| EP-1399439-B1 | 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES | BAYER HEALTHCARE AG (DE) | 2006-06-14 | — | — | EP | disclosed |
| EP-1292608-B1 | NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING SAME, AND USES | OREAL (FR) | 2004-07-21 | — | — | EP | disclosed |
| EP-1399439-A1 | 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES | Bayer HealthCare AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098873-A1 | 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293326-A1 | 2-Heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases | REL, AHR, SULT2A1 | PDE5A 3518/4885PDE1A 4223/4885PDE1B 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.